AlphAIalphai — Financial news for AI agents
GuruFocusAPR 12 min read$VNRX

VolitionRX (VNRX) Rating Maintained as Buy by D. Boral Capital

Analyst Jason Kolbert from D. Boral Capital has maintained a 'Buy' rating for VolitionRX (VNRX) with an unchanged price target of $3.00 USD. This reiteration reflects consistent confidence in the company's prospects, with historical ratings showing a steady 'Buy' status. The average target price from 5 analysts is $2.06, suggesting a significant upside of 984.21% from the current price, while GuruFocus estimates a fair value of $1.40 for VNRX.

Original reporting
GuruFocus · NULL
Published Apr 1, 2026, 5:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 6:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
VolitionRX (VNRX) Rating Maintained as Buy by D. Boral Capital — source image
Source · GuruFocus
Decision brief

The 30-second read

$VNRXBullishHigh
01

Why it matters

The reaffirmed 'Buy' rating and upside potential could attract investor interest, possibly leading to short-term price appreciation.

02

Market read

The news is highly relevant for investors interested in biotech stocks, especially those focusing on cancer diagnostics and early-stage biotech companies.

03

What to watch

Potential delays in clinical trials, regulatory hurdles, or market sentiment shifts could impact stock performance negatively.

Timing: short-term (next 1-3 months)

Background

The news reflects analyst confidence in VNRX, a biotech company in the life sciences sector, with a focus on its valuation and rating stability.

Company-level read

Ticker impact

$VNRXBullishHigh confidence
Context

The news pertains directly to VolitionRX (VNRX), a biotech company in the life sciences sector, with a strong bullish sentiment from analysts.

Expected impact

Moderate to high increase in stock price over the next 1-3 months, contingent on market conditions and company performance.

Evidence & confidence

Multiple analysts maintain a bullish outlook with a substantial upside, supported by consistent ratings and a fair value estimate above current price.

Market effects

Sector

Positive sentiment for biotech and life sciences sectors, potentially boosting related stocks.

Regional

Limited regional impact; primarily relevant to US biotech sector.

Global

Moderate; biotech sector is globally interconnected, but specific to US-listed biotech stocks.

Counterpoint

What could challenge this read

Some analysts may view the high upside as overly optimistic, especially given the speculative nature of biotech stocks.

Key entities

  • Company
    VolitionRX

    A biotech company specializing in cancer diagnostics.

  • Financial Institution
    D. Boral Capital

    An investment firm providing analyst ratings.

Read at source← All news

Related articles

AUG 8
$NVDAMed

Nvidia to Invest Up to $3 Billion in Blackstone

The Information reported Nvidia plans to invest up to $3 billion in Lancium, a Blackstone-backed power and data center infrastructure developer tied to the Stargate AI initiative. Nvidia would initially put in $2 billion for a 20% stake, with up to $1 billion more contingent on performance thresholds. No company comment was provided.

econotimes.com4 min
AUG 8
$NVDAMed

Nvidia to invest up to US$3 billion in Stargate data centre developer Lancium: The Information

Nvidia plans to invest up to $3 billion in Lancium, the developer of the Stargate data center campus in Texas, The Information reported. Nvidia would invest $2 billion for about a 20% stake, with an additional $1 billion possible based on grid hookup thresholds. Lancium’s land and power portfolio has an enterprise value near $10 billion, and it may explore an IPO in 2027.

businesstimes.com.sg4 min
AUG 8
$USARMed

Is USA Rare Earth (USAR) Overvalued On Its DOE Funding And Tokenization Buzz?

Simply Wall St says USA Rare Earth (USAR) shares have rebounded after being selected by the U.S. Department of Energy for up to $19.3M in federal funding, pending final negotiations, for a pilot-scale rare earth separations project. The article cites mixed valuation views, with a “fair value” of $0.33 versus a DCF estimate of $83.09, and notes recent price returns.

simplywall.st6 min
AUG 8
$000660.KSMed

SK Hynix mulling options for US$3 bil Chongqing plant — Bloomberg

Bloomberg reports SK Hynix is exploring options for its Chongqing, China semiconductor packaging and testing plant, including possibly bringing in an investor. A potential stake sale could value the facility at about US$3 billion, according to people familiar. Separately, SK Hynix plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND, citing AI-driven demand.

theedgemalaysia.com4 min
AUG 8
$OESXMed

Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting

Orion Energy Systems (NASDAQ:OESX) reported FY2026 revenue targets of $95M to $97M and expects positive adjusted EBITDA for the year, after margin gains at its annual meeting. LED lighting revenue rose to $55.9M from $47.7M, with gross margin up to 33.8%. EV charging revenue fell to $14.4M from $16.8M, while maintenance revenue rose to $16.0M.

yahoo.com4 min